PortalPublikationenDetection rate of PET/CT in patients with biochemical relaps...

Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC

Standard

Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC. / Berliner, Christoph; Tienken, Milena; Frenzel, Thorsten; Kobayashi, Yuske; Helberg, Annabelle; Kirchner, Uve; Klutmann, Susanne; Beyersdorff, Dirk; Budäus, Lars; Wester, Hans-Jürgen; Mester, Janos; Bannas, Peter.

in: EUR J NUCL MED MOL I, Jahrgang 44, Nr. 4, 04.2017, S. 670-677.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung

Harvard

Berliner, C, Tienken, M, Frenzel, T, Kobayashi, Y, Helberg, A, Kirchner, U, Klutmann, S, Beyersdorff, D, Budäus, L, Wester, H-J, Mester, J & Bannas, P 2017, 'Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC', EUR J NUCL MED MOL I, Jg. 44, Nr. 4, S. 670-677. https://doi.org/10.1007/s00259-016-3572-5

APA

Berliner, C., Tienken, M., Frenzel, T., Kobayashi, Y., Helberg, A., Kirchner, U., Klutmann, S., Beyersdorff, D., Budäus, L., Wester, H-J., Mester, J., & Bannas, P. (2017). Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC. EUR J NUCL MED MOL I, 44(4), 670-677. https://doi.org/10.1007/s00259-016-3572-5

Vancouver

Berliner C, Tienken M, Frenzel T, Kobayashi Y, Helberg A, Kirchner U et al. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC. EUR J NUCL MED MOL I. 2017 Apr;44(4):670-677. https://doi.org/10.1007/s00259-016-3572-5

Bibtex

@article{8509f84e0c2941f29de83f1238ab4899,
title = "Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC",
abstract = "PURPOSE: To determine the detection rate of PET/CT in biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and to compare it with published detection rates of [(68)Ga]PSMA HBED-CC.METHODS: We performed a retrospective analysis in 83 consecutive patients with documented biochemical relapse after prostatectomy. All patients underwent whole body [(68)Ga]PSMA I&T PET/CT. PET/CT images were evaluated for presence of local recurrence, lymph node metastases, and distant metastases. Proportions of positive PET/CT results were calculated for six subgroups with increasing prostate specific antigen (PSA) levels (<0.5 ng/mL, 0.5 to <1.0 ng/mL, 1.0 to <2.0 ng/mL, 2.0 to <5.0 ng/mL, 5.0 to <10.0, ≥10.0 ng/mL). Detection rates of [(68)Ga]PSMA I&T were statistically compared with published detection rates of [(68)Ga]PSMA HBED-CC using exact Fisher's test.RESULTS: Median PSA was 0.81 (range: 0.01 - 128) ng/mL. In 58/83 patients (70 %) at least one [(68)Ga]PSMA I&T positive lesion was detected. Local recurrent cancer was present in 18 patients (22 %), lymph node metastases in 29 patients (35 %), and distant metastases in 15 patients (18 %). The tumor detection rate was positively correlated with PSA levels, resulting in detection rates of 52 % (<0.5 ng/mL), 55 % (0.5 to <1.0 ng/mL), 70 % (1.0 to <2.0 ng/mL), 93 % (2.0 to <5.0 ng/mL), 100 % (5.0 to <10.0 ng/mL), and 100 % (≥10.0 ng/mL). There was no significant difference between the detection rate of [(68)Ga]PSMA I&T and published detection rates of [(68)Ga]PSMA HBED-CC (all p>0.05).CONCLUSIONS: [(68)Ga]PSMA I&T PET/CT has high detection rates of recurrent prostate cancer that are comparable to [(68)Ga]PSMA HBED-CC.",
author = "Christoph Berliner and Milena Tienken and Thorsten Frenzel and Yuske Kobayashi and Annabelle Helberg and Uve Kirchner and Susanne Klutmann and Dirk Beyersdorff and Lars Bud{\"a}us and Hans-J{\"u}rgen Wester and Janos Mester and Peter Bannas",
year = "2017",
month = apr,
doi = "10.1007/s00259-016-3572-5",
language = "English",
volume = "44",
pages = "670--677",
journal = "EUR J NUCL MED MOL I",
issn = "1619-7070",
publisher = "Springer",
number = "4",

}

RIS

TY - JOUR

T1 - Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC

AU - Berliner, Christoph

AU - Tienken, Milena

AU - Frenzel, Thorsten

AU - Kobayashi, Yuske

AU - Helberg, Annabelle

AU - Kirchner, Uve

AU - Klutmann, Susanne

AU - Beyersdorff, Dirk

AU - Budäus, Lars

AU - Wester, Hans-Jürgen

AU - Mester, Janos

AU - Bannas, Peter

PY - 2017/4

Y1 - 2017/4

N2 - PURPOSE: To determine the detection rate of PET/CT in biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and to compare it with published detection rates of [(68)Ga]PSMA HBED-CC.METHODS: We performed a retrospective analysis in 83 consecutive patients with documented biochemical relapse after prostatectomy. All patients underwent whole body [(68)Ga]PSMA I&T PET/CT. PET/CT images were evaluated for presence of local recurrence, lymph node metastases, and distant metastases. Proportions of positive PET/CT results were calculated for six subgroups with increasing prostate specific antigen (PSA) levels (<0.5 ng/mL, 0.5 to <1.0 ng/mL, 1.0 to <2.0 ng/mL, 2.0 to <5.0 ng/mL, 5.0 to <10.0, ≥10.0 ng/mL). Detection rates of [(68)Ga]PSMA I&T were statistically compared with published detection rates of [(68)Ga]PSMA HBED-CC using exact Fisher's test.RESULTS: Median PSA was 0.81 (range: 0.01 - 128) ng/mL. In 58/83 patients (70 %) at least one [(68)Ga]PSMA I&T positive lesion was detected. Local recurrent cancer was present in 18 patients (22 %), lymph node metastases in 29 patients (35 %), and distant metastases in 15 patients (18 %). The tumor detection rate was positively correlated with PSA levels, resulting in detection rates of 52 % (<0.5 ng/mL), 55 % (0.5 to <1.0 ng/mL), 70 % (1.0 to <2.0 ng/mL), 93 % (2.0 to <5.0 ng/mL), 100 % (5.0 to <10.0 ng/mL), and 100 % (≥10.0 ng/mL). There was no significant difference between the detection rate of [(68)Ga]PSMA I&T and published detection rates of [(68)Ga]PSMA HBED-CC (all p>0.05).CONCLUSIONS: [(68)Ga]PSMA I&T PET/CT has high detection rates of recurrent prostate cancer that are comparable to [(68)Ga]PSMA HBED-CC.

AB - PURPOSE: To determine the detection rate of PET/CT in biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and to compare it with published detection rates of [(68)Ga]PSMA HBED-CC.METHODS: We performed a retrospective analysis in 83 consecutive patients with documented biochemical relapse after prostatectomy. All patients underwent whole body [(68)Ga]PSMA I&T PET/CT. PET/CT images were evaluated for presence of local recurrence, lymph node metastases, and distant metastases. Proportions of positive PET/CT results were calculated for six subgroups with increasing prostate specific antigen (PSA) levels (<0.5 ng/mL, 0.5 to <1.0 ng/mL, 1.0 to <2.0 ng/mL, 2.0 to <5.0 ng/mL, 5.0 to <10.0, ≥10.0 ng/mL). Detection rates of [(68)Ga]PSMA I&T were statistically compared with published detection rates of [(68)Ga]PSMA HBED-CC using exact Fisher's test.RESULTS: Median PSA was 0.81 (range: 0.01 - 128) ng/mL. In 58/83 patients (70 %) at least one [(68)Ga]PSMA I&T positive lesion was detected. Local recurrent cancer was present in 18 patients (22 %), lymph node metastases in 29 patients (35 %), and distant metastases in 15 patients (18 %). The tumor detection rate was positively correlated with PSA levels, resulting in detection rates of 52 % (<0.5 ng/mL), 55 % (0.5 to <1.0 ng/mL), 70 % (1.0 to <2.0 ng/mL), 93 % (2.0 to <5.0 ng/mL), 100 % (5.0 to <10.0 ng/mL), and 100 % (≥10.0 ng/mL). There was no significant difference between the detection rate of [(68)Ga]PSMA I&T and published detection rates of [(68)Ga]PSMA HBED-CC (all p>0.05).CONCLUSIONS: [(68)Ga]PSMA I&T PET/CT has high detection rates of recurrent prostate cancer that are comparable to [(68)Ga]PSMA HBED-CC.

U2 - 10.1007/s00259-016-3572-5

DO - 10.1007/s00259-016-3572-5

M3 - SCORING: Journal article

C2 - 27896369

VL - 44

SP - 670

EP - 677

JO - EUR J NUCL MED MOL I

JF - EUR J NUCL MED MOL I

SN - 1619-7070

IS - 4

ER -